Neither Outcomes4Me nor any participants in or contributors to any webinar, article or content endorses or recommends any products or services. Consult your physician regarding any treatment or therapy.
We recently hosted a webinar called “Optimizing NSCLC Treatment with Biomarker Testing Insights”, featuring Dr. Jessica Lin of Mass General Cancer Center. In it, Dr. Lin discussed how biomarker testing identifies genetic mutations and resistance mechanisms in non-small cell lung treatment, informs better treatment decisions, and influences patient care. Listen to the replay and learn about the latest advancements that are transforming NSCLC treatment and driving improved patient outcomes.
**A summary of the discussion is below**
Biomarker testing is a transformative tool in lung cancer diagnosis and treatment, providing patients and doctors with critical information to select the most effective treatments. However, the differences between biomarker testing, genomic testing, and genetic testing can be confusing. Here, we break down these terms and highlight why biomarker testing is essential for personalized lung cancer care.
What Is Biomarker Testing?
Lung cancer isn’t a single disease; it comprises various subtypes with distinct characteristics. Biomarker testing helps identify these unique features, allowing oncologists to understand a specific cancer’s genetic alterations or protein expression levels. By detecting these biomarkers, doctors can determine the best treatment options, including targeted therapies and immunotherapies, tailored to an individual’s cancer profile.
For example, testing for proteins like PD-L1 helps gauge a patient’s likelihood of responding to immunotherapy. Unlike basic genetic testing, biomarker testing covers a broad range of factors, including both genetic mutations and protein levels, to provide a comprehensive cancer profile.
Biomarker Testing vs. Genetic Testing: Key Differences
Patients often wonder how biomarker testing compares to genetic testing. While they sound similar, these two forms of testing have distinct purposes:
Biomarker Testing: More comprehensive, biomarker testing includes genetic alterations in cancer cells and other factors like protein expression. It’s also called “molecular testing” and goes beyond simply looking at gene mutations.
Genetic Testing: Often refers to testing for hereditary mutations, which are inherited from parents and may be passed down to children. This type of testing, typically done on a blood sample, is different from cancer-specific genetic alterations identified through tumor biopsies.
In lung cancer, biomarker testing focuses on mutations within cancer cells rather than inherited mutations. This distinction is crucial, as biomarker results inform cancer treatment rather than identifying inherited risks.
Why Is Biomarker Testing Important?
Biomarker testing is a vital step in NSCLC diagnosis and treatment planning. It helps identify whether a patient’s tumor contains mutations that may respond to specific treatments. Early biomarker testing can reveal essential treatment options, helping oncologists avoid a “one-size-fits-all” approach and instead customize therapies based on each tumor’s unique profile.
Empowering Patients to Ask About Biomarker Testing
Given its importance, biomarker testing should be part of the initial cancer diagnosis. Patients should feel empowered to ask their doctors about it, ensuring that all relevant tests are conducted. Understanding these distinctions allows patients to take an active role in their treatment decisions, paving the way for personalized, effective care.
By clarifying biomarker testing, this post aims to empower patients to discuss this critical testing with their healthcare providers and make informed treatment decisions tailored to their specific cancer type.
